Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Absci will apply its generative AI platform to The Kennedy Institute’s immunology biorepository to speed the discovery and development of multiple therapies

Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, and the University of Oxford's Kennedy Institute of Rheumatology, a biomedical research center developing new therapies for chronic inflammatory and musculoskeletal conditions, today announced a partnership to create breakthrough therapies for immune-mediated diseases.

It takes an average of ten years and costs more than $1 billion to bring a new drug to market. This partnership will leverage Absci's Integrated Drug Creation™ platform, with its unique combination of generative AI and synthetic biology capabilities, and The Kennedy Institute's leading clinical immunology datasets to identify antibodies to immune-mediated inflammatory diseases and autoimmune conditions with a higher probability of clinical success at unprecedented speeds.

Absci will use generative AI models with The Kennedy Institute's genomics datasets to identify novel antibodies from patients with exceptional immune responses to inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. Then, using its reverse immunology approach, Absci will computationally reassemble antigen-antibody pairs as promising potential starting points for drug development.

'The Kennedy Institute's vast, high-quality biorepository data expands Absci's strategic R&D portfolio and aims to unlock major advances for a range of immune-mediated conditions that millions suffer from,' said Sean McClain, Founder and CEO of Absci. 'Together with our established data partnerships with St. John's Cancer Institute and Aster Insights, this partnership gives Absci a robust data pipeline that enables our AI platform across a wide range of therapeutic areas as we build our internal therapeutic pipeline.'

'Absci's reverse immunology approach promises to turn clinical data into pharmaceutical drugs,' said Christopher Buckley, Director of Clinical Research at The Kennedy Institute. 'We are excited about the potential for generative AI to accelerate the discovery of promising drug candidates and better understand theirpotential efficacy and safety profiles. This partnership will help accelerate our findings in the clinic into new immunotherapies for patients.'

The Kennedy Institute is a pioneer in autoimmunity and one of the first to show how suppressing tumor necrosis factor (TNF) could reduce harmful inflammatory processes in various diseases. Today, some best-selling drugs (e.g., adalimumab) are based on this innovative therapeutic approach. Absci and The Kennedy Institute will work together to accelerate the discovery and development of other promising drug targets and therapies.